phrykt

Xeris Biopharma Holdings, Inc. (XERS): who owns it and who trades it

As of Nov 16, 2026, XERS insiders reported 35 open-market sales worth $5.8M and no purchases in the last 12 months, with 78% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin McCulloch (See Remarks), with $1.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Xeris Biopharma Holdings

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns XERS

239 funds and institutions reported XERS shares worth $867M at the end of Q2 2026, about 63% of the company. The largest holder is BlackRock, Inc. with 8.4%.

Funds and institutions (13F) 63%Everyone else 37%

10 largest owners, by share of the company

BlackRock, Inc.8.4%
D. E. Shaw & Co., Inc.4.5%
Vanguard Capital Management LLC4.3%
State Street Corp2.8%
Geode Capital Management, LLC2.7%
Nuveen, LLC2.5%
Rosalind Advisors, Inc.1.7%
Qube Research & Technologies Ltd1.7%
Vanguard Portfolio Management LLC1.5%
Wellington Management Group LLP1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.14.53M8.41%$115M+12%
D. E. Shaw & Co., Inc.7.80M4.52%$61.8M+0%
Vanguard Capital Management LLC7.34M4.25%$58.1M+5%
State Street Corp4.82M2.79%$38.2M+4%
Geode Capital Management, LLC4.72M2.73%$37.4M+10%
Nuveen, LLC4.39M2.54%$34.7M+50%
Rosalind Advisors, Inc.2.91M1.68%$23M-10%
Qube Research & Technologies Ltd2.89M1.68%$22.9M-30%
Vanguard Portfolio Management LLC2.63M1.52%$20.8M-1%
Wellington Management Group LLP2.37M1.37%$18.7M+9%
Morgan Stanley2.34M1.35%$18.5M-9%
Legal & General Group Plc2.01M1.17%$15.9M+5%
Armistice Capital, LLC1.96M1.13%$15.5M+3%
Two Sigma Investments, LP1.89M1.09%$14.9M-2%
Parkman Healthcare Partners LLC1.81M1.05%$14.3M+5%
Algert Global LLC1.74M1.01%$13.8M+51%
Northern Trust Corp1.60M0.93%$12.7M+11%
Goldman Sachs Group Inc1.59M0.92%$12.6M-1%
AQR Capital Management LLC1.54M0.89%$12.2M+11%
Charles Schwab Investment Management Inc1.49M0.86%$11.8M+10%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, XERS insiders reported $0 of open-market purchases and $5.8M of sales. 78% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.8M
35 trades, 9 people
Sales under a 10b5-1 plan
78%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 6, 2026

Purchases and sales by month

$1.2M$1.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Kevin McCullochSee RemarksSale plan25,000$12.49$312KForm 4
Nov 2, 2026Beth HechtSee RemarksSale plan25,000$10.23$256KForm 4
Nov 2, 2026Kevin McCullochSee RemarksSale plan15,000$10.23$153KForm 4
Nov 2, 2026Steven PieperSee RemarksSale plan5,000$10.23$51.2KForm 4
Oct 1, 2026Beth HechtSee RemarksSale plan16,666$9.41$157KForm 4
Oct 1, 2026Kevin McCullochSee RemarksSale plan15,000$9.41$141KForm 4
Oct 1, 2026Steven PieperSee RemarksSale plan5,000$9.41$47KForm 4
Sep 28, 2026Kevin McCullochSee RemarksSale plan25,000$10.00$250KForm 4
Sep 1, 2026Kevin McCullochSee RemarksSale plan15,000$8.49$127KForm 4
Sep 1, 2026Beth HechtSee RemarksSale plan16,666$8.49$141KForm 4
Sep 1, 2026Steven PieperSee RemarksSale plan5,000$8.50$42.5KForm 4
Aug 12, 2026Steven PieperSee RemarksSale plan5,000$8.50$42.5KForm 4
Aug 3, 2026Kevin McCullochSee RemarksSale plan15,000$8.02$120KForm 4
Aug 3, 2026Beth HechtSee RemarksSale plan16,666$8.01$133KForm 4
Jul 7, 2026Steven PieperSee RemarksSale plan27,600$8.52$235KForm 4
Jul 6, 2026Steven PieperSee RemarksSale plan17,400$8.50$148KForm 4
Jul 1, 2026Kevin McCullochSee RemarksSale plan90,000$8.03$723KForm 4
Jul 1, 2026Beth HechtSee RemarksSale plan16,666$8.03$134KForm 4
Jun 4, 2026Dawn HalkuffDirectorSale plan20,000$6.09$122KForm 4
Jun 4, 2026Barbara-Jean Anne Bormann-KennedyDirectorSale plan16,000$6.09$97.4KForm 4
Jun 4, 2026John JohnsonDirectorSale plan15,000$6.09$91.3KForm 4
Jun 3, 2026Marla PerskyDirectorSale plan15,500$5.90$91.5KForm 4
Jun 1, 2026Beth HechtSee RemarksSale plan16,667$6.06$101KForm 4
May 1, 2026Beth HechtSee RemarksSale plan16,667$6.23$104KForm 4
Apr 1, 2026Beth HechtSee RemarksSale plan16,667$5.99$99.8KForm 4
Mar 30, 2026James Aloysius BradyDirectorSale plan10,834$5.54$60KForm 4
Mar 2, 2026Beth HechtSee RemarksSale plan16,567$6.24$103KForm 4
Mar 2, 2026Beth HechtSee RemarksSale plan100$7.06$706Form 4
Feb 2, 2026Beth HechtSee RemarksSale16,667$7.45$124KForm 4
Jan 8, 2026Kevin McCullochSee RemarksSale plan15,000$8.00$120KForm 4
Jan 5, 2026John Patrick Shannon JrDirectorSale24,907$7.08$176KForm 4
Jan 2, 2026Beth HechtSee RemarksSale plan16,667$7.43$124KForm 4
Dec 19, 2025John JohnsonDirectorSale135,400$7.22$978KForm 4
Dec 12, 2025Barbara-Jean Anne Bormann-KennedyDirectorSale plan15,000$7.09$106KForm 4
Dec 1, 2025Beth HechtSee RemarksSale plan16,667$7.01$117KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin McCullochSee Remarks–$1.9MNov 5, 2026
Beth HechtSee Remarks–$1.6MNov 2, 2026
John JohnsonDirector–$1.1MJun 4, 2026
Steven PieperSee Remarks–$566KNov 2, 2026
Barbara-Jean Anne Bormann-KennedyDirector–$204KJun 4, 2026
John Patrick Shannon JrSee Remarks, Director–$176KJan 5, 2026
Dawn HalkuffDirector–$122KJun 4, 2026
Marla PerskyDirector–$91.5KJun 3, 2026
James Aloysius BradyDirector–$60KMar 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

XERS short interest

Low short interest. 4.9% of XERS shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went down 27%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.99M XERS shares were sold short, 4.9% of the shares outstanding, up 11.9% from the report before. At the average daily volume of 2.07M shares, buying them all back would take about 4.3 trading days (days to cover).

Shares short, % of all shares

4.93%May 15Oct 307.94%

Days to cover

4.3May 15Oct 3010.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.99M4.93%+12%2.07M4.3
Oct 15, 20268.03M4.40%+11%2.46M3.3
Sep 30, 20267.20M3.95%-11%4.15M1.7
Sep 15, 20268.06M4.42%+0%1.67M4.8
Aug 31, 20268.04M4.41%-8%1.47M5.5
Aug 14, 20268.73M4.79%-5%1.97M4.4
Jul 31, 20269.22M5.06%-9%1.37M6.8
Jul 15, 202610.08M5.84%-21%2.30M4.4
Jun 30, 202612.76M7.39%-0%2.34M5.4
Jun 15, 202612.81M7.42%+2%1.75M7.3
May 29, 202612.51M7.25%+1%1.33M9.4
May 15, 202612.36M7.16%-22%2.13M5.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Xeris Biopharma Holdings company events

Xeris Biopharma Holdings filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Nov 2, 2026LeadershipThe Board of Directors of Xeris Biopharma Holdings, Inc. increased the size of the Board from eight (8) to nine (9) members, thereby creating a vacancy on the Board, and appointed Menassie Taddese to fill such vacancy. Filing
  3. Oct 14, 2026AnnouncementXeris Biopharma Holdings, Inc., through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey against defendants (i) Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals… Filing
  4. Sep 9, 2026AnnouncementShared information with investors. Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jul 17, 2026AnnouncementBelow with respect to the Shares (as defined herein) is incorporated into this Item 3.02 by reference, insofar as it relates to the unregistered sales of equity securities. Filing
  7. Jun 30, 2026LeadershipThe Board of Directors of Xeris Biopharma Holdings, Inc. increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy, effective as of July 1, 2026. Filing
  8. Jun 11, 2026AnnouncementThe Company issued a press release announcing entry into the Exchange Agreements. Filing
  9. Jun 5, 2026VoteReported shareholder vote results. Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Apr 21, 2026LeadershipDr. Jeffrey Sherman, a member of the Board of Directors of Xeris Biopharma Holdings, Inc., provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company’s 2026 Annual Meeting of Stockholders. Filing
  12. Mar 2, 2026ResultsReleased financial results. Filing
  13. Feb 27, 2026AnnouncementShared information with investors. Filing
  14. Jan 8, 2026ResultsReleased financial results. Filing
  15. Dec 1, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Xeris Biopharma Holdings financials

Famous investors that hold XERS

4 of the 50 well-known investors we track reported holding XERS in their latest 13F filing. The largest position is Steve Cohen's, worth $20.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20262.13M$20.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026277,664$2.7M0.0%+1152%
Israel Englander · Millennium ManagementQ3 2026245,814$2.3M0.0%+87%
Ken Griffin · Citadel AdvisorsQ3 2026169,287$1.6M0.0%-75%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named XERS in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 30, 2026Vanguard Capital Management13G/A5.0%

Questions about Xeris Biopharma Holdings, Inc. (XERS) stock

Who owns the most XERS stock?

The largest reported owner of Xeris Biopharma Holdings, Inc. (XERS) is BlackRock, Inc., with 8.4% of the company. In total, 239 funds and institutions reported holding XERS at the end of Q2 2026, together about 63% of the shares. See the largest owners.

Are XERS insiders buying or selling?

In the last 12 months, XERS insiders reported no open-market purchases and 35 sales worth $5.8M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in XERS?

As of Oct 30, 2026, 8.99M XERS shares were sold short, 4.9% of the shares outstanding, up 11.9% from the report before. At the average daily volume of 2.07M shares, buying them all back would take about 4.3 trading days (days to cover). See the history.

Which famous investors hold XERS?

4 of the 50 well-known investors we track reported XERS in their latest 13F filing, including Steve Cohen, Paul Tudor Jones, Israel Englander. The largest position is worth $20.3M. See all holders.

Executive pay

Xeris Biopharma Holdings's chief executive was paid a total of $5M for the year ended Dec 31, 2025. In the last 12 months, Xeris Biopharma Holdings's executives and directors bought no stock on the open market and sold $6M.

Chief executive, total pay$5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$12MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.